Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status

被引:23
作者
Frauchiger, A. L. [1 ]
Mangana, J. [1 ]
Rechsteiner, M. [2 ]
Moch, H. [2 ]
Seifert, B. [3 ]
Braun, R. P. [1 ]
Dummer, R. [1 ]
Goldinger, S. M. [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Inst Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland
[3] Univ Zurich, Epidemiol Biostat & Prevent Inst, Dept Biostat, Zurich, Switzerland
关键词
METASTATIC MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; PATHOLOGICAL FEATURES; IMPROVED SURVIVAL; MEK INHIBITION; NRAS; S-100B; VEMURAFENIB; CANCER; V600E;
D O I
10.1111/bjd.14347
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Activating mutations of BRAF provide an important treatment target in patients with melanoma. The prognostic role of several biochemical markers in relation to mutation status is not clear. Objectives To analyse the prognostic significance of BRAF mutation in patients with melanoma and correlate it to different markers. Methods In total, 162 patients with stage IV melanoma and known BRAF mutation status were included. Clinical, histopathological and laboratory information was collected and compared between patients with BRAF mutant (BRAFm) and wild-type (BRAFwt) melanoma at the time of first distant metastasis. Results In total, 88 patients (54%) had BRAFm melanoma (V600E/V600K). At the first distant metastasis, S100B levels in BRAFm patients were more frequently elevated (P = 0.01) and significantly higher (P = 0.02). Median overall survival (mOS) was significantly longer in BRAFwt patients with normal compared with patients with elevated S100B levels (P < 0.01). In BRAFm melanoma, elevated S100B levels showed no prognostic influence (P = 0.18). Elevated lactate dehydrogenase (LDH) levels had a significantly negative impact on mOS in both groups. mOS was increased for BRAFm patients treated with a BRAF inhibitor (BRAFi) compared with BRAFm patients not receiving BRAFi (P = 0.01). No difference in mOS between BRAFm patients who did not receive BRAFi treatment and BRAFwt patients was observed. Conclusions Better mOS was observed in BRAFm patients treated with BRAFi. BRAFm patients not treated with BRAFi show similar survival curves to BRAFwt patients. Elevated LDH is a BRAF-independent prognostic parameter; S100B has prognostic significance in BRAFwt melanoma only.
引用
收藏
页码:823 / 830
页数:8
相关论文
共 40 条
  • [1] The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
    Ardekani, Gholamreza Safaee
    Jafarnejad, Seyed Mehdi
    Tan, Larry
    Saeedi, Ardavan
    Li, Gang
    [J]. PLOS ONE, 2012, 7 (10):
  • [2] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [3] BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site
    Bauer, Juergen
    Buettner, Petra
    Murali, Rajmohan
    Okamoto, Ichiro
    Kolaitis, Nicholas A.
    Landi, Maria T.
    Scolyer, Richard A.
    Bastian, Boris C.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (02) : 345 - 351
  • [4] The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma
    Bonfrer, JMG
    Korse, CM
    Nieweg, OE
    Rankin, EM
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (12) : 2210 - 2214
  • [5] Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    Carlino, Matteo S.
    Todd, Jason R.
    Gowrishankar, Kavitha
    Mijatov, Branka
    Pupo, Gulietta M.
    Fung, Carina
    Snoyman, Stephanie
    Hersey, Peter
    Long, Georgina V.
    Kefford, Richard F.
    Rizos, Helen
    [J]. MOLECULAR ONCOLOGY, 2014, 8 (03) : 544 - 554
  • [6] Clinical significance of BRAF mutations in metastatic melanoma
    Chang D.Z.
    Panageas K.S.
    Osman I.
    Polsky D.
    Busam K.
    Chapman P.B.
    [J]. Journal of Translational Medicine, 2 (1)
  • [7] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516
  • [8] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [9] Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
    Devitt, Bianca
    Liu, Wendy
    Salemi, Renato
    Wolfe, Rory
    Kelly, John
    Tzen, Chin-Yuan
    Dobrovic, Alexander
    McArthur, Grant
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (04) : 666 - 672
  • [10] S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles
    Donato, R
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (07) : 637 - 668